Core Viewpoint - CarMax, Inc. is under investigation for potential violations of federal securities laws, following a significant decline in sales and earnings attributed to a temporary demand boost from U.S. tariffs on cars [1][2][3] Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into CarMax for possible securities law violations [1] - The investigation is prompted by discrepancies between CarMax's claims of strong demand and the reality of declining sales figures [2] Group 2: Financial Performance - In fiscal Q2 2025, CarMax reported a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [3] - The company's net earnings for Q2 were approximately $95.4 million, down from $132.8 million in the previous year, indicating a significant drop in profitability [3] - Following the earnings report, CarMax's stock price fell by $11.45 per share, or about 20%, from $57.05 to $45.60 [3]

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/bellring-brands-inc-class-action-lawsuit. Why is BellRing Being Investigated? BellRing Brands operates in the convenient nutrition category. The Compa ...

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were disappointing and raised concerns about the drug's regulatory approval and commercial viability [3]. - The stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025, following the announcement of the trial results [3]. Legal Implications - Investors in MoonLake are encouraged to seek legal options due to the potential violations of securities laws related to the trial results [1][4]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering significant amounts for clients [6].

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. ("Brunello Cucinelli" or the "Company") (OTCMKTS: BCUCY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Brunello Cucinelli and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On Septe ...

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) for allegedly concealing significant cost overruns and execution problems on key infrastructure projects, leading to a sharp decline in stock value and investor confidence [1][3][4]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver among its three segments [2]. Allegations and Issues - The lawsuit claims that FLR concealed cost overruns and execution issues on major projects such as the Gordie Howe International Bridge, I-635/LBJ, and I-35, which were impacted by subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategies and failed to disclose the full impact of reduced client spending and macroeconomic uncertainty [3]. Financial Performance - Despite the ongoing issues, FLR reaffirmed its financial guidance in May 2025. However, on August 1, 2025, the company reported second-quarter results that significantly missed expectations, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disappointing results, FLR cut its full-year guidance and experienced a stock price drop of 27.04%, closing at $41.42 on August 1, 2025. Analysts subsequently downgraded the stock due to lost confidence in management's disclosures and project oversight [4].

Group 1 - A class action has been filed against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who acquired its securities between May 7, 2025, and August 5, 2025 [1][2] - The allegations include that LifeMD misled investors about its competitive position and failed to properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [2] - Following the announcement of its second quarter 2025 results and a revision of its full-year guidance, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can choose to remain absent class members if they do not wish to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for failing to disclose a material investigation by the U.S. Department of Justice regarding potential violations of the False Claims Act [2][3]. Group 1: Allegations and Investigations - Semler Scientific is accused of not disclosing an investigation by the DOJ into possible violations of the False Claims Act during the class period from March 10, 2021, to April 15, 2025 [2]. - The company received an initial civil investigative demand (CID) from the DOJ in July 2017, which investigated whether it violated the False Claims Act by marketing certain tests as reimbursable by Medicare [3]. - On February 11, 2025, Semler Scientific engaged in unsuccessful settlement discussions with the DOJ, raising concerns about a potential lawsuit [3]. Group 2: Financial Impact - Following the revelation of the investigation on February 28, 2025, Semler Scientific's stock price dropped by $4.03, or 9.38%, closing at $38.89 on March 3, 2025 [3]. - After the company announced a settlement agreement with the DOJ for $29.75 million on April 15, 2025, the stock fell by $3.40, or 9.88%, to close at $31.00 on April 16, 2025 [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must submit their paperwork by October 28, 2025, to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery, and they can remain absent class members if they choose [5].

Core Viewpoint - A class action securities lawsuit has been filed against PubMatic, Inc. due to alleged securities fraud affecting investors between February 27, 2025, and August 11, 2025 [1][2] Group 1: Lawsuit Details - The complaint alleges that PubMatic's management made false statements and concealed critical information regarding a major demand side platform buyer shifting clients to a new platform, leading to reduced ad spend and revenue for PubMatic [2] - The lawsuit claims that the positive statements made by the defendants about PubMatic's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fluor Corporation ("Fluor Corporation" or the "Company") (NYSE: FLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fluor Corporation investors who were adversely affected by alleged securities fraud between February 18, 2025 and July 31, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/fluor-cor ...

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Shares of social network Snap Inc. (NYSE: SNAP) fell 6.6% after investment firm Mizuho reportedly initiated coverage on the company with a Neutral rating and a $9 price target. Mizuho purportedly described the company as a “show-me story” and cited weak feedback from Snap’s advertising channels. This analyst action comes on the heels of a federal securities class action lawsuit filed against Snap and certain senior executives, alleging the company presented a ...